Articles On Antisense Therapeutics (ASX:ANP)

The ASX 200 Health Index (XHJ) is trading higher by 0.27% at the time of writing, compared to the broader index which is down by 0.40%. Fertility company Virtus Health (ASX:VRT) is being pursued by a takeover offer from BGH Capital. BGH, wh...

Antisense Therapeutics (ANP) receives a positive decision for the UK Paediatric Investigation Plan (PIP) submission for the development of its drug for Duchenne muscular dystrophy The decision came from the Medicines and Healthcare product...

The Antisense Therapeutics Limited (ASX: ANP) share price is rising on the back of positive investor sentiment on Thursday. This comes after the company provided an update on its application for ATL1102 with the United States Food and Drug...

The ASX 200 Health Index (XHJ) is down by 0.20% at the time of writing, compared to the broader index which is down by 0.35%. Brain-focused company, Argenica Therapeutics (ASX:AGN), has just been awarded a US patent relating to the use of i...

Antisense Therapeutics (ANP) has submitted its ATL1102 inhibitor toxicology protocol to the US FDA to support extended clinical dosing The nine-month chronic monkey toxicology study will support the dosing of patients with the inhibitor be...

ShareCafeDue Diligence Webinar – Antisense Therapeutics (ASX: ANP)   In a first time exclusive hear from Managing Director & CEO – Mark Diamond, Chair – Charmaine Gittleson & Non-Executive Director – Gill Price. Antisense Therapeut...

ShareCafeANP – Morgans rates the stock as Speculative Buy Now that Antisense Therapeutics has raised $20m via an institutional placement at $0.24 (along with a 1 for 2 free-attaching options), Morgans raises its target price to $0.58 from $...

ShareCafeWebinar Recap – ANP, ELT, HLX, CLU Catch up on the full webinar with presentations from Antisense Therapeutics (ASX: ANP), Elementos (ASX: ELT), Helix Resources (ASX: HLX) & Cluey Learning (ASX: CLU). Webinar Recap – ANP, ELT,...

ShareCafeAntisense Therapeutics (ASX: ANP) – Webinar Presentation Mark Diamond – Managing Director and CEO –  Antisense Therapeutics is a biotechnology company, developing and commercializing antisense pharmaceuticals for large unmet marke...

Shares in Antisense Therapeutics Limited (ASX: ANP) are tumbling today following a heavily oversubscribed placement. At the time of writing, the Antisense share price is trading at 22 cents, down 8.33%. This means that its shares have now...

Antisense Therapeutics (ASX:ANP) has announced positive news from the Paediatric Committee of the European Medicines Agency and the successful completion of a capital raise.

Shares in biopharmaceutical company Antisense Therapeutics Limited (ASX: ANP) made an abrupt downturn today and finished the session 18.64% lower at 24 cents apiece. The Antisense Therapeutics share price fell sharply after the company r...

The ASX 200 rose 0.64% on the first trading day of the month. All sectors were in the green except financials – a sector dragged down by Westpac (ASX:WBC) following its results. The best sectors were consumer discretionaries, telcos and uti...

The Paediatric Committee (PDCO) of the European Medicines Agency (EMA) has given a positive final opinion on Antisense Therapeutics’ (ANP) Paediatric Investigation Plan Provides ANP with confidence to conduct a phase 2b/three trial in Euro...

ASX-listed drug developer Antisense Therapeutics has raised $20 million in an institutional placement and will turn its attention to securing another $17 million via a rights issue.

After a positive Monday to Thursday, the ASX wiped out gains made across the week, losing more than 1% today The ASX followed a plunge on Wall Street with the ASX 200 closing at 7,324, which was 1.44% lower than yesterday’s close. While Wal...

Local stocks lost ground on Thursday, with minor falls at the big end of town and a slightly steeper drop of ~0.8% for the microcap Emerging Markets Index. The ASX opened with a weak lead from Wall Street, after a fortnight of steady gains...

An additional news report on the recommendation, valuation, forecast and opinion changes for ASX-listed equities. In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArena has now added The Au...

ShareCafeThe Week that Was – October 4-9, 2021 We at ShareCafe understand you are busy and may not have been left with enough time to keep up with the quality content we’ve been bringing you throughout the week. To make it easier to do so,...

ShareCafeAntisense Duchenne’s Trial Set for Approval? Antisense Therapeutics (ASX: ANP) reported on Friday 30 September (2021), that it had received a draft opinion recommending agreement with the company’s Paediatric Investigation Plan (PI...

Antisense Therapeutics (ASX:ANP) has announced it has received a draft opinion recommending the agreement with its Paediatric Investigation Plan for the development of ATL1102 for Duchenne muscular dystrophy from the Paediatric Comm...

The ASX 200 health stocks index (XHJ) is down by 0.82% at the time of writing, compared to the broader ASX 200 index which is down by 0.08% Respiratory tech specialist, Adherium (ASX:ADR), jumped 12% this morning after saying it was awarded...

Welcome to the FNArena Corporate Results Monitor. Today's Reports: ((A2M)) - a2 Milk Co ((AIM)) - Ai-Media Technologies ((AGI)) - Ainsworth Game Technology ((AIZ)) - Air New Zealand ((ANP)) - Antisense Therapeutics ((APX)) - Appen ((ALG))...

It’s been a mixed two weeks for small-cap health companies, with only 45 companies gaining ground, 76 losing it and 23 flatlining. Rhinomed (ASX:RNO) was the biggest gainer, up a massive 85% for the fortnight after scoring a contract with N...

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

ShareCafeThe Week that Was – August 2-6, 2021 We at ShareCafe understand you are busy and may not have been left with enough time to keep up with the quality content we’ve been bringing you throughout the week. To make it easier to do so, h...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week Healthcare...

Antisense Therapeutics (ASX:ANP) has announced that non-executive director Dr Charmaine Gittleson will transition to succeed Bob Moses as the chair of its board.

An additional news report on the recommendation, valuation, forecast and opinion changes for ASX-listed equities. In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArena has now added The Au...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays. Theme of the week Healthcare fi...

Antisense Therapeutics (ASX:ANP) has announced a new R&D collaboration with researchers at the Murdoch Children’s Research Institute’s to further investigate the potential of its ATL1102.

Over the past month, a number of US FDA approvals have moved the share prices of global pharma stocks, including those traded here on the ASX. The biggest FDA announcement during the month came out of US-based Biogen, which received a contr...

Antisense Therapeutics (ASX:ANP) has announced that it has received feedback on the Paediatric Investigation Plan for the development of ATL1102 for Duchenne muscular dystrophy from the Paediatric Committee of the European Medicines...

ShareCafeAlzheimer’s Decision Sends Positive Message to Aussie Biotechs The US Food and Drug Administration’s landmark but controversial approval of a new treatment for Alzheimer’s disease suggests a sea change in the regulator’s attitude t...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week It has been...

The Antisense Therapeutics Limited (ASX: ANP) share price soared today without any news out of the company. It seems the market may have been a bit slow on the uptake and was responding to news released by the junior healthcare company earl...

Summary PuriflOH urged the government to use effective airborne transmission prevention technology such as PuriflOH devices in hotel quarantine. The 9SP’s share price has shot up by 13.3% to AU$0.017, clocking a high volume of over 48....

ShareCafeWhat the FDA Feedback Means for Antisense Therapeutics (ASX:ANP) Former Chief Medical Officer for CSL Charmaine Gitleson gives insight into why she joined the ANP board and the FDA process, and how this Type C meeting fits into cla...

Small caps have dipped for a second straight day following their seven-day winning streak. The Small Ordinaries index closed yesterday down 12.1 points, or 0.37 per cent, to 3,278.8. Larger companies fared a little bit better, with the ASX2...

Antisense Therapeutics (ASX:ANP) has provided a progress update on the manufacture of clinical supplies for its planned Phase IIb clinical trial of ATL1102 in non-ambulant Duchenne patients.

The Antisense Therapeutics Limited (ASX: ANP) share price finished the day higher today following a progress update. At market close, shares in the biotechnology company ended the day at 21 cents, up 5%. What did Antisense announce? In its...

Xero (XRO), NEXTDC (NXT), Eagers Automotive (APE), Atlas Arteria (ALX), and Antisense Therapeutics (ANP).

ShareCafeHidden Gems Webinar Recap – LAU, NOX, TZL, ANP, VMS Catch up on the full webinar with presentations from  Antisense Therapeutics (ASX: ANP), Lindsay Australia (ASX: LAU), Noxopharm (ASX: NOX), Venture Minerals (ASX: VMS) & TZ...

Summary Drug development and clinical services company Emyria has obtained Class IIa TGA registration for its medical-grade monitoring tool, Openly. With this TGA registration, Emyria is in a leading position to develop Real World Evid...

An additional news report on the recommendation, valuation, forecast and opinion changes for ASX-listed equities. In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArena has now added The Au...

Small caps have bounced back from a slow start to finish in the green – barely. The Small Ordinaries index finished Friday up 2.6 points, or 0.08 per cent, to 3,318.8, slightly underperforming the All Ordinaries which rose 0.12 per cent. Th...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week With stock...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week The ASX he...

Antisense Therapeutics (ASX:ANP) has announced the appointment of Dr Charmaine Gittleson as a new non-executive director of the company.

An additional news report on the recommendation, valuation, forecast and opinion changes for ASX-listed equities. In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArena has now added The Au...